Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25680255 | 0.88 | TRPV1 (0.41) | SCN10AABL1GSK3BMAPTGSK3A | |
| SCHEMBL25680300 | 0.87 | ABL1 (0.40) | SCN10AABL1GSK3BMAPTGSK3A | |
| SCHEMBL30464221 | 0.87 | ABL1 (0.40) | SCN10AABL1GSK3BMAPTGSK3A | |
| SCHEMBL25680302 | 0.85 | KCNQ3 (0.44) | — | |
| SCHEMBL25680336 | 0.84 | MAPT (0.38) | ABL1GSK3BMAPTACACB | |
| SCHEMBL25679837 | 0.83 | GSK3B (0.39) | ABL1GSK3BMAPTGSK3AACACB | |
| SCHEMBL25680317 | 0.83 | ABL1 (0.51) | ABL1 | |
| SCHEMBL25680256 | 0.82 | ABL1 (0.37) | SCN10AABL1GSK3BMAPTGSK3A | |
| SCHEMBL25697694 | 0.79 | PTGER4 (0.40) | SCN10AABL1GSK3BMAPTACACB | |
| SCHEMBL25697889 | 0.78 | TRPV1 (0.37) | SCN10AKMT2AUSP2F10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | SCN10A 16/4885ABL1 3596/4885KMT2A 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.